Track 13: Vaccine Safety & Efficacy


Antibody adequacy alludes to the capacity of immunizations to achieve the proposed useful consequences for inoculated people in a characterized populace under perfect states of utilization. The potential advantages of a successful immunization – for example advancement of wellbeing and prosperity, and assurance from ailment and its physical, mental and financial outcomes must be weighed against the potential danger of an antagonistic occasion following vaccination (AEFI) with that immunization. Antibody related hazard is the likelihood of an unfavorable or undesirable result happening, and the seriousness of the subsequent mischief to the wellbeing of inoculated people in a characterized populace following vaccination with an immunization under perfect states of utilization.


  • Influenza Vaccines
  • Measles Vaccines

Related Conference of Track 13: Vaccine Safety & Efficacy

November 19-20, 2025

6th International Conference on Vaccine Research

Tokyo, Japan
March 16-17, 2026

8th World Congress on Vaccine and Immunology

Paris, France
September 21-22, 2026

44th Euro Global Summit and Expo on Vaccines & Vaccination

Barcelona, Spain

Track 13: Vaccine Safety & Efficacy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in